名古屋大学 · 医学
Hayashi教授の研究室は、がんの転移メカニズムと予後予測の分子標 Biomarker の解明を柱としています。特に、肝細胞癌（HCC）における遺伝子のエピジェネティクス的制御や、手術縁の分子マーキングによる再発予測の確立を目指しています。臨床応用に直結する分子診断技術の開発も進めており、がん治療の個別化と予後改善に貢献することを目的としています。
Figures are computed from collected data and may differ slightly.
Pancreatic cancer frequently metastasized to distant LNs via a complex pathway and developed into systemic disease. Aggressive multimodality therapy, including neoadjuvant therapy, is essential to improve the long-term survival of patients at substantial risk of distant LN metastasis.
Triple-combination array analysis successfully identified COL1A1 as a candidate survival-related gene in HCCs. Epigenetic down-regulation of COL1A1 mRNA expression might have a role as a prognostic biomarker of HCC.
A panel of gene methylation targets in deep surgical margin imprints provides a potential predictive marker of postoperative locoregional recurrence. Intraoperative use of molecular margin imprint analysis may assist surgeons in obtaining rigorously negative surgical margins and improve the outcome of head and neck surgery.
The current data suggest that AKAP12 is downregulated in cancer tissues through promoter hypermethylation, and may have a role as a candidate tumor suppressor gene for HCC.
Open papers in the app to read, cite, and organize with AI.
